From the Journals

Cochrane report: HPV vaccine proves its worth in adolescent, young adult women

 

Key clinical point: HPV vaccines targeting HPV16 and HPV18 significantly reduced the risk of precancerous cervical lesions in women aged 15-26 years.

Major finding: The vaccines reduced the risk of precancer caused by HPV16 and HPV18 from 341 per 10,000 to 157 per 10,000 (RR, 0.46).

Study details: The review was based on data from 26 studies including 73,428 women worldwide over 8 years.

Disclosures: The Cochrane Library sponsored the study. Several of the researchers received travel grants from GlaxoSmithKline or MSD-Sanofi-Pasteur.

Source: Arbyn M et al. Cochrane Database Syst Rev. 2018. doi: 10.1002/14651858.CD009069.pub3.


 

FROM THE COCHRANE LIBRARY


Several of the researchers received travel grants from GlaxoSmithKline or MSD-Sanofi-Pasteur.

SOURCE: Arbyn M et al. Cochrane Database Syst Rev. 2018. doi: 10.1002/14651858.CD009069.pub3.

Next Article: